X

Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.

X

Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.

IMAGES ARE PROVIDED BY Pacific Biosciences ON AN "AS-IS" BASIS. Pacific Biosciences DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, OWNERSHIP, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL Pacific Biosciences BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER WITH RESPECT TO THE IMAGES.

You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences
Contact:
Friday, February 26, 2021

Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conferences

MENLO PARK, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conferences: Cowen Annual Health Care Conference on Monday, March 1, 2021 at 1:20 p.m. EST Barclays Global Healthcare Conference on Wednesday, March 10, 2021 at 2:25 p.m. EST The live webcasts can be accessed at the company’s investors page at investor.pacificbiosciences.com. The replays will be available for at least 30 days following the presentation. About Pacific Biosciences Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read…

Read More »

Wednesday, February 24, 2021

Children’s Mercy Kansas City Expands Investment in Pacific Biosciences Sequel IIe Systems to Scale Up Whole Genome Research Initiatives Focused on Rare Disease Diagnosis

PacBio’s highly accurate HiFi sequencing will help clinical researchers identify disease-causing genetic variants and increase our understanding of rare diseases KANSAS CITY, Mo. and MENLO PARK, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced that Children’s Mercy Kansas City, one of the nation’s top pediatric medical centers, has increased its investment in highly accurate HiFi sequencing with four new Sequel IIe Systems to add to its two existing Sequel IIe Systems. These additional systems will significantly increase Children’s Mercy’s large-scale whole genome sequencing capacity…

Read More »

Thursday, February 18, 2021

Pacific Biosciences Sequel II Systems Deployed to Scale-Up Global Viral Surveillance Initiatives Focused on COVID-19

Labcorp Using PacBio’s HiFi Sequencing to Detect SARS-CoV-2 Variants in the U.S. MENLO PARK, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced that Labcorp (NYSE: LH), a leading global life sciences company, has increased its commitment to highly accurate HiFi sequencing with the addition of new PacBio® Sequel® II Systems. The new systems will expand Labcorp’s capacity to generate thousands of more complete coronavirus genomes from patient samples each week. These data are being used by the United States (U.S.) Centers for Disease Control…

Read More »

Wednesday, February 10, 2021

Pacific Biosciences of California, Inc. Announces Fourth Quarter and Fiscal Year 2020 Financial Results

MENLO PARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2020. Reported revenue is consistent with the Company’s press release issued on January 11, 2021. Q4 2020 Financial Highlights Revenue for the fourth quarter of 2020 was $27.1 million, representing a 42% increase sequentially compared with $19.1 million for the third quarter of 2020 and a 3% decrease compared with $27.9 million for the fourth quarter of 2019. The Company placed 35 Sequel II/IIe systems during the fourth quarter, bringing the total…

Read More »

Wednesday, February 10, 2021

Pacific Biosciences Announces $900 Million Investment from SoftBank to Support Growth Initiatives

MENLO PARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company”), a leading provider of high-quality, long-read sequencing platforms, today announced that SB Management, a subsidiary of Softbank Group Corp., will make an investment of $900 million in convertible senior notes to support the Company’s future growth initiatives. “This strategic investment by SoftBank validates our leadership position in the long-read DNA sequencing market and enables us to further accelerate our growth strategies”, said Christian Henry, President and Chief Executive Officer of Pacific Biosciences. “Currently, we offer one of the most accurate and complete…

Read More »

Friday, February 5, 2021

Pacific Biosciences Grants Equity Incentive Award to New Employee

MENLO PARK, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock and restricted stock units (“RSU”) covering 50,000 shares of Pacific Biosciences common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan on December 14, 2020 (the “2020 Inducement Plan”). The 2020 Inducement Plan is used…

Read More »

Friday, January 29, 2021

Pacific Biosciences Grants Equity Incentive Award to New Employee

MENLO PARK, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 110,000 shares of Pacific Biosciences common stock and restricted stock units (“RSU”) covering 55,000 shares of Pacific Biosciences common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan on December 14, 2020 (the “2020 Inducement Plan”). The 2020 Inducement Plan is used…

Read More »

Wednesday, January 27, 2021

Pacific Biosciences of California, Inc. Fourth Quarter 2020 Financial Results Call

MENLO PARK, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its fourth quarter 2020 financial results on Wednesday, February 10, 2021, at 4:30pm Eastern Time. The call will be webcast and may be accessed at Pacific Biosciences’ website at: https://investor.pacificbiosciences.com/. Date: February 10, 2021 Time: 4:30pm ET Listen via Internet: https://investor.pacificbiosciences.com/ Toll-free: 888.366.7247 International: 707.287.9330 Conference ID: 8096067 Replay: https://investor.pacificbiosciences.com About Pacific Biosciences Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on…

Read More »

Wednesday, January 27, 2021

Pacific Biosciences of California, Inc. Fourth Quarter 2020 Financial Results Call

MENLO PARK, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its fourth quarter 2020 financial results on Wednesday, February 10, 2021, at 4:30pm Eastern Time. The call will be webcast and may be accessed at Pacific Biosciences’ website at: https://investor.pacificbiosciences.com/. Date: February 10, 2021 Time: 4:30pm ET Listen via Internet: https://investor.pacificbiosciences.com/ Toll-free: 888.366.7247 International: 707.287.9330 Conference ID: 8096067 Replay: https://investor.pacificbiosciences.com About Pacific Biosciences Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on…

Read More »

Wednesday, January 13, 2021

Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform

New platform expected to make whole genome sequencing significantly more affordable and accessible for use in mainstream medical care MENLO PARK, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced a multi-year collaboration with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to begin development of a production-scale high-throughput sequencing platform leveraging the power of PacBio’s highly accurate HiFi sequencing to expand Invitae’s whole genome testing capabilities. “Whole genome sequencing has the ability to significantly improve diagnosis for a wide range of diseases and…

Read More »

Tuesday, January 12, 2021

Pacific Biosciences Grants Equity Incentive Awards to New Employees

MENLO PARK, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality, long read sequencing platforms, today announced that the Board of Directors granted non-qualified stock options covering an aggregate of 750,000 shares of Pacific Biosciences common stock and restricted stock units (“RSUs”) covering 335,000 shares of Pacific Biosciences common stock to the Company’s recently hired Chief Operating Officer, Mark Van Oene, under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “Inducement Plan”) effective on January 8, 2021. The Board of Directors also granted non-qualified…

Read More »

Monday, January 11, 2021

Pacific Biosciences of California, Inc. Announces Preliminary Fourth Quarter 2020 Revenue

MENLO PARK, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (the “Company”) (NASDAQ: PACB), a leading provider of high-quality sequencing platforms, today announced unaudited preliminary revenue of approximately $27 million for its fourth quarter ended December 31, 2020. The Company’s full financial results for the fourth quarter and the fiscal year ended December 31, 2020 are not yet available. Financial and Operational Highlights Preliminary fourth quarter revenue is expected to be approximately $27 million, representing an estimated increase of approximately 41% sequentially compared with $19.1 million for the third quarter of 2020. The Company placed 35…

Read More »

Friday, January 8, 2021

Pacific Biosciences Announces Appointments of Mark Van Oene as Chief Operating Officer and Peter Fromen as Chief Commercial Officer

MENLO PARK, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing solutions, today announced the appointments of Mark Van Oene as Chief Operating Officer and Peter Fromen as Chief Commercial Officer, both effective as of January 8, 2021. “I am delighted to have Mark Van Oene and Peter Fromen join the company,” said Christian Henry, President and Chief Executive Officer of Pacific Biosciences. “Mark and Peter are both world-class executives and their deep experience in the field of genomics will significantly strengthen our management team as we execute on…

Read More »

Friday, January 8, 2021

Wellcome Sanger Institute Increases Investment in PacBio Long-Read Sequencing to Support Darwin Tree of Life Research Initiative

Seven new Sequel IIe Systems will support expanded generation of high-quality genomes for improving fundamental understanding of biology and aiding biodiversity conservation MENLO PARK, Calif ., Jan. 08, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality, long-read sequencing platforms, today announced that the Wellcome Sanger Institute has committed to purchase seven new Sequel IIe Systems and upgrade its five existing Sequel II Systems to increase its long-read sequencing capabilities for projects including the Darwin Tree of Life (DToL; all eukaryotes in Britain and Ireland) and Aquatic Symbiosis Genomics (ASG; host-symbiont pairs) programs. Launched…

Read More »

Friday, December 18, 2020

Pacific Biosciences Grants Equity Incentive Award to New Employee

MENLO PARK, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock and restricted stock units (“RSU”) covering 50,000 shares of Pacific Biosciences common stock to a recently hired non-executive officer employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan on December 14, 2020 (the “Effective Date”). The 2020 Inducement Equity Incentive…

Read More »

1 2 3 17

Subscribe for blog updates:

Archives